# Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)

> **NCT05712720** · PHASE2 · COMPLETED · sponsor: **Rezolute** · enrollment: 94 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Experimental: Group 1 - 50mg RZ402
- **DRUG:** Experimental: Group 2 - 200mg RZ402
- **DRUG:** Experimental: Group 3 - 400mg RZ402
- **OTHER:** Placebo: Group 4 - Placebo

## Key facts

- **NCT ID:** NCT05712720
- **Lead sponsor:** Rezolute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-06
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712720, "Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05712720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*